Alterity Therapeutics (ASX:ATH) Marketable Securities: A$0.00 Mil (As of Dec. 2025)


ASX:ATH Alterity Therapeutics Ltd ASX:ATH
34 GF Score
Price A$0.65
View Full Analysis

What is Alterity Therapeutics Marketable Securities?

Alterity Therapeutics ASX:ATH -8.45% 34 Marketable Securities is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:ATH with a GF Score™ of 34/100.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Alterity Therapeutics's Marketable Securities for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Alterity Therapeutics's annual Marketable Securities stayed the same from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$0.00 Mil) but then increased from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$7.50 Mil).

Alterity Therapeutics  (ASX:ATH) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Alterity Therapeutics Marketable Securities Related Terms

Alterity Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Marketable Securities Chart

Alterity Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 7.50

Alterity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 7.50 0.00 0.00 0.00
ASX:ATH
34GF Score
Alterity Therapeutics Ltd ASX:ATH
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of A$0.00 Mil mean?
Alterity Therapeutics (ASX:ATH) has a Marketable Securities of A$0.00 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Alterity Therapeutics and its competitors.
Is Alterity Therapeutics' Marketable Securities too high?
Alterity Therapeutics' current Marketable Securities is A$0.00 Mil. Overall, Alterity Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Marketable Securities compare to VRTX and REGN?
Alterity Therapeutics' Marketable Securities of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current Marketable Securities is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current Marketable Securities of A$0.00 Mil. The current Marketable Securities is A$0.00 Mil. Alterity Therapeutics' overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current Marketable Securities is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
34GF Score

Get the complete analysis for ASX:ATH

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.65
Price